What is Leerink Partnrs’ Estimate for ABT Q2 Earnings?

Abbott Laboratories (NYSE:ABT) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Abbott Laboratories in a research note issued on Monday, June 16th. Leerink Partnrs analyst M. Kratky anticipates that the healthcare product maker will post earnings of $1.26 per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Abbott Laboratories’ current full-year earnings is $5.14 per share. Leerink Partnrs also issued estimates for Abbott Laboratories’ Q3 2025 earnings at $1.30 EPS, Q4 2025 earnings at $1.48 EPS, Q1 2026 earnings at $1.24 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.45 EPS, Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $5.74 EPS, FY2027 earnings at $6.34 EPS, FY2028 earnings at $6.97 EPS and FY2029 earnings at $7.64 EPS.

A number of other equities research analysts have also weighed in on the company. Royal Bank of Canada lifted their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Thursday, April 17th. Citigroup boosted their price target on Abbott Laboratories from $135.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Barclays boosted their price target on Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a research note on Thursday, April 17th. Stifel Nicolaus upped their target price on Abbott Laboratories from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, April 17th. Finally, Jefferies Financial Group upped their target price on Abbott Laboratories from $135.00 to $137.00 and gave the company a “hold” rating in a research note on Thursday, April 17th. Six research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $142.61.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $133.99 on Tuesday. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23. The stock’s 50-day moving average price is $131.70 and its 200 day moving average price is $126.58. The stock has a market capitalization of $233.12 billion, a PE ratio of 17.51, a price-to-earnings-growth ratio of 2.52 and a beta of 0.73. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.02. The firm had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%.

Institutional Trading of Abbott Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 0.7% during the first quarter. Vanguard Group Inc. now owns 169,823,136 shares of the healthcare product maker’s stock valued at $22,527,039,000 after purchasing an additional 1,177,739 shares during the last quarter. Capital International Investors grew its holdings in shares of Abbott Laboratories by 3.4% during the fourth quarter. Capital International Investors now owns 67,972,953 shares of the healthcare product maker’s stock valued at $7,688,160,000 after purchasing an additional 2,229,026 shares during the last quarter. Capital Research Global Investors grew its holdings in shares of Abbott Laboratories by 1.5% during the fourth quarter. Capital Research Global Investors now owns 54,097,005 shares of the healthcare product maker’s stock valued at $6,118,903,000 after purchasing an additional 795,073 shares during the last quarter. Geode Capital Management LLC grew its holdings in Abbott Laboratories by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 35,668,834 shares of the healthcare product maker’s stock worth $4,023,027,000 after buying an additional 765,636 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in Abbott Laboratories by 12.8% in the 1st quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker’s stock worth $3,948,117,000 after buying an additional 3,371,113 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the sale, the director now directly owns 34,058 shares of the company’s stock, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.76%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 30.61%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.